Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
NCT04739111Phase 1Completed
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lesabelimab and cdp1 in cancer, sponsored by Dragonboat Biopharmaceutical. Primary endpoints: Incidence of adverse events up to 5 months, Dose Limiting Toxicities up to 24 months and 1 more. Started Jan 2021; status: completed.
02
Drugs
lesabelimabcdp1
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04739111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739111.